KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Repurchased
Ratios

Emergent BioSolutions (EBS) Short-Term Debt repayments: 2019-2024

Historic Short-Term Debt repayments for Emergent BioSolutions (EBS) over the last 3 years, with Sep 2024 value amounting to $222.7 million.

  • Emergent BioSolutions' Short-Term Debt repayments rose 471.03% to $222.7 million in Q3 2024 from the same period last year, while for Sep 2024 it was $296.2 million, marking a year-over-year decrease of 61.02%. This contributed to the annual value of $284.2 million for FY2024, which is 28.74% down from last year.
  • According to the latest figures from Q3 2024, Emergent BioSolutions' Short-Term Debt repayments is $222.7 million, which was up 294.16% from $56.5 million recorded in Q2 2024.
  • Emergent BioSolutions' Short-Term Debt repayments' 5-year high stood at $353.0 million during Q3 2020, with a 5-year trough of $5.0 million in Q1 2024.
  • For the 2-year period, Emergent BioSolutions' Short-Term Debt repayments averaged around $113.8 million, with its median value being $47.8 million (2023).
  • Its Short-Term Debt repayments has fluctuated over the past 5 years, first spiked by 2,253.33% in 2020, then slumped by 83.76% in 2024.
  • Emergent BioSolutions' Short-Term Debt repayments (Quarterly) stood at $353.0 million in 2020, then reached $12.0 million in 2023, then skyrocketed by 471.03% to $222.7 million in 2024.
  • Its Short-Term Debt repayments was $222.7 million in Q3 2024, compared to $56.5 million in Q2 2024 and $5.0 million in Q1 2024.